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Abstract: A new significance test is proposed to substantiate scientific
findings from multiple primary studies investigating the same re-
search hypothesis. The test statistic is based on the harmonic mean of
the squared study-specific test statistics and can also include weights.
Appropriate scaling ensures that, for any number of studies, the null
distribution is a χ2-distribution with one degree of freedom. The null
distribution can be used to compute a one-sided p-value or to ensure
Type-I error control at a pre-specified level. Further properties are dis-
cussed and a comparison with FDA’s two-trials rule for drug approval
is made, as well as with alternative research synthesis methods. An at-
tractive feature of the new approach is that a claim of success requires
each study to be convincing on its own to a certain degree depending
on the significance level and the number of studies. As a by-product,
the approach provides a calibration of the sceptical p-value recently
proposed for the analysis of replication studies.
Key Words: harmonic mean χ2 test; Lévy distribution; Type-I error
control; two-trials rule; sceptical p-value
1. Introduction
Research synthesis has been characterized as the process of combining the results of
multiple primary studies aimed at testing the same conceptual hypothesis. Meta-
analysis is the preferred technique of quantitative research synthesis, as it provides
overall effect estimates with confidence intervals and p-values through pooling and
allows for the incorporation of heterogeneity between studies. However, meta-analysis
can be criticized as a too weak technique if the goal is to substantiate an original claim
through one or more additional independent studies. Specifically, a significant result
may occur in a meta-analysis even if some of the individual studies have not been
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convincing on its own, perhaps even with effect estimates in the wrong direction. This
may be acceptable if the unconvincing studies have been small, but seems less tolerable
if each study was well-powered and well-conducted.
For example, consider the results from 5 clinical trials on the effect of Carvedilol,
a beta- and alpha-blocker and an antioxidant drug for the treatment of patients with
moderate to severe heart failure patients, on mortality (cf . Fisher, 1999a, Table 1).
One-sided p-values (from log-rank tests) and hazard ratios (HR) are shown in Table 1,
indicating a consistent reduction in mortality between 28 and 78% across the different
studies.
study number p-value HR log HR SE
240 0.0245 0.22 -1.51 0.85
221 0.1305 0.57 -0.56 0.51
220 0.00025 0.27 -1.31 0.41
239 0.2575 0.53 -0.63 1.02
223 0.128 0.72 -0.33 0.29
Table 1: Results from 5 clinical trials on the effect of Carvedilol for the treatment of
patients with moderate to severe heart failure patients. Shown are one-sided
p-values, hazard ratios (HR), and the associated log hazard ratios (log HR)
with standard errors (SE).
A meta-analysis could be applied to the data shown in Table 1, but the drug regu-
lation industry (including the U.S. ”Food and Drug Administration, or FDA) typically
relies instead on the "two-trials rule" (Kay, 2015, Section 9.4), also known as the “two
pivotal study paradigm” (Hlavin et al., 2016), for approval. This simple decision rule
requires “at least two adequate and well-controlled studies, each convincing on its
own, to establish effectiveness” (FDA, 1998, p. 3). This is usually achieved by inde-
pendently replicating the result of a first study in a second study, both significant at
one-sided level α = 0.025. However, in modern drug development often more than
two trials are conducted and it is unclear how to extend the two-trials rule to this
setting. Requiring at least 2 out of n > 2 studies to be significant is too lax a criterion
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if the results from the non-significant studies are not taken into account at all. On
the other hand, requiring all n studies to be significant is too stringent. This problem
applies to the Carvedilol example, where two trials are significant at the 2.5% level
(one just with p = 0.0245) but where it is unclear whether the remaining three studies
(with p-values 0.1305, 0.2575 and 0.128) can be considered as sufficiently “convincing
on its own.”
This has led statistical researchers to discuss the possibility of pooling the results
from the different studies into one p-value (Fisher, 1999b; Darken and Ho, 2004; Shun
et al., 2005). Ronald Fisher’s method to combine p-values (Fisher, 1958) is often used
for this task, e. g. in Fisher (1999a) for the Carvedilol example. However, Fisher’s
method shares the problems of a meta-analysis as it can produce a significant overall
result even if one of the trials was negative. For example, one completely unconvincing
trial with (one-sided) p = 0.5 combined with a convincing second one with p = 0.0001
would give Fisher’s p = 0.0005 < 0.000625 = 0.0252, so a claim of success with
respect to the Type I error rate of the two-trials rule. On the other hand, two trials
both with p = 0.01 would not be considered as successful with Fisher’s p = 0.001.
Both decisions seem undesirable from a regulator’s perspective. Another problem is
that Fisher’s method treats large and small studies equally. It can be extended to
incorporate weights (Good, 1955), but then the null distribution does no longer have a
convenient form.
The two-trials rule therefore remains the standard in drug regulation, but has ad-
ditional deficiencies even for n = 2 studies, where independent p-value thresholding
at 0.025 may lead to decisions that are the opposite to what the evidence warrants.
For example, two trials both with p = 0.024 will lead to drug approval but carry less
evidence for a treatment effect than one trial with p = 0.026 and the other one with
p = 0.001, which would, however, not pass the two-trials rule. Rosenkrantz (2002) has
therefore proposed a method to claim efficacy if one of two trials is significant while
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the other just shows a trend. He combines the two-trials rule with Fisher’s method
and a relaxed criterion for significance of the two individual trials, say 2α. A similar
approach has been proposed by Maca et al. (2002) using Stouffer’s pooled rather than
Fisher’s combined method. The arbitrariness in the choice of the relaxed significance
criterion is less attractive, though, and it is not obvious how to extend the methods to
results from more than two studies.
In this paper I develop a new method that addresses these issues and leads to more
appropriate inferences, the harmonic mean χ2 test described in Section 2. At the Type-I
error rate 0.0252 of the two-trials rule, the proposed test comes to opposite conclusions
for the examples mentioned above: In contrary to Fisher’s method, it leads to approval
of two trial both with p = 0.01, but not to approval if one has p = 0.0001 and the other
one p = 0.5. Contrary to the two-trials rule, it leads to approval of one trial with
p = 0.026 and the other one with p = 0.001, but not to approval if both trials have
p = 0.024. The work is motivated from a recent proposal how to evaluate the success of
replication studies (Held, 2020) and is based on the harmonic mean of the squared Z-
scores. It can include weights for the individual studies and can be calibrated to ensure
exact Type-I error control. Furthermore, the new approach implies useful bounds
on the individual study-specific p-values p1, . . . , pn, thus formalizing the meaning of
“at least two adequate and well-controlled studies, each convincing on its own”. The
approach will be compared to the two-trials rule and illustrated on the Carvedilol
data in Section 3. Section 4 outlines how the method can be used to calibrate the
sceptical p-value (Held, 2020). I close with some discussion in Section 5.
2. The harmonic mean χ2 test
Suppose one-sided p-values p1, . . . , pn are available from n independent studies. How
can we combine the p-values into one p-value? Cousins (2007) compares some of the
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more prominent papers on this topic. Among them is Stouffer’s method, which is
based on the Z-scores Zi = Φ−1(1− pi), here Φ−1(.) denotes the quantile function of
the standard normal distribution. Under the assumption of no effect, the test statistic
Z = ∑ni=1 Zi/
√
n is standard normally distributed. The corresponding p-value forms
the basis of the “pooled-trials rule” and is equivalent to investigate significance of the
overall effect estimate from a fixed-effects meta-analysis (Senn, 2007, Section 12.2.8). It
can also be extended to include weights. Fisher’s method is also commonly used and
compares −2∑ni=1 log pi with a χ2-distribution with 2 n degrees of freedom to compute
a combined p-value.
Here I propose a different quantity to assess the overall evidence for a treatment
effect based on the harmonic mean Z2H = n/∑
n
i=1 1/Z
2
i of the squared Z-scores:
χ2 = n Z2H =
n2
n
∑
i=1
1/Z2i
. (1)
This form is motivated from the special case of n = 2 successive studies, one original
and one replication, where a reverse-Bayes approach for the assessment of replication
success has recently been described (Held, 2020). If the two studies have equal preci-
sion (i. e. sample size), the assessment of replication success does not depend on the
order of the two studies and is based on the test statistic 1/(1/Z21 + 1/Z
2
2), compare
Held (2020, equation (9)). Equation (1) extends this to n studies with an additional
multiplicative factor n2, which ensures that the null distribution of χ2 does not de-
pend on n. As a by-product, this enables us to calibrate the sceptical p-value proposed
in Held (2020, Section 3), see Section 4 for details.
Weights w1, . . . ,wn can also be introduced in (1), then the test statistic
χ2w =
w2
n
∑
i=1
wi/Z2i
where w =
n
∑
i=1
√
wi (2)
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should be used. Multiplication with w2 ensures that the null distribution of χ2w does
not depend on the weights w1, . . . ,wn nor on n.
The specific form of (2) deserves some additional comments. In practice we often
have Zi = θˆi/σi where σi = κ2/mi is the standard error of the effect estimate θˆi, κ2 is
the one-unit variance and mi the effective sample size of study i. If we use weights
wi = 1/σ2i equal to the precision of the effect estimates, (2) can be written as the
unweighted harmonic mean θˆ2H of the squared effect estimates θˆ
2
i times a scaling factor
w2/n:
χ2w = w
2/n · θˆ2H where w =
n
∑
i=1
√
mi. (3)
In the special case of equal study-specific sample sizes m1 = . . .mn = m, the scaling
factor reduces to nm.
There is a subtle difference between the two formulations (1) and (3). The un-
weighted test statistic (1) is based on the harmonic mean of the squared study-specific
test statistics Z2i , i = 1, . . . , n. If we increase the sample size of the different studies,
(1) will therefore also tend to increase if there is a true non-zero effect. However, the
test statistic (3) is based on the harmonic mean θˆ2H of the squared study-specific ef-
fect estimates θˆ2i , which should not be much affected by any increase of study-specific
sample sizes because the study-specific estimates θˆi should then stabilize around their
true values. It is the scaling factor w2/n that will react to an increase in study-specific
sample sizes. The test statistic (3) can thus be factorized into a component depending
on sample sizes and a component depending on effect sizes.
Using properties of Lévy distributions it can be shown that under the null hypo-
thesis of no effect, the distribution of both (1) and (2) is χ2 with one degree of freedom,
see Appendix A for details. We can thus compute an overall p-value pH from (1) or
(2) based on the χ2(1) distribution function. However, we have to be careful since (1)
does not take the direction of the effects into account. Usually we are interested in a
pre-defined direction of the underlying effect, say H1: θ > 0 against H0: θ = 0 and we
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will have to adjust for the fact that (1) and (2) can be large for any of the 2n possible
combinations of the signs on Z1, . . . , Zn, with all these combinations being equally
likely under the null hypothesis. Since we are interested only in the case where all
signs are positive, we have to adjust the p-value accordingly.
To be specific, suppose all studies have a positive effect and the observed test statistic
(1) or (2) is χ2 = y, respectively χ2w = y. The overall p-value from the proposed
significance test is then
pH = Pr(χ2(1) ≥ y)/2n = [1−Φ(√y)] /2n−1. (4)
Likewise we can obtain the critical value
cH =
[
Φ−1(1− 2n−1αH)
]2
(5)
for the test statistic (1) or (2) to control the Type-I error rate at some overall significance
level αH. Note that the overall p-value (4) cannot be larger than 1/2n as it should, since
under the null hypothesis the probability to obtain n positive results is 1/2n. We are
only interested in this case, so if at least one of the studies has a negative effect we
suggest to report the inequality pH > 1/2n, for example pH > 0.25 for n = 2 studies.
In what follows I restrict attention to the unweighted test statistic χ2 given in (1),
similar results can be obtained for χ2w given in (2). Let Zi = zi denote the observed test
statistic in the i-th study. I assume that zi > 0 for all i = 1, . . . , n, i. e. all effects go in the
right direction. First note that the smallest squared test statistic z2min = min{z21, . . . , z2n}
multiplied by the number of studies n is an upper bound on the harmonic mean
z2H = n/∑
n
i=1 1/z
2
i :
z2min ≤ z2H ≤ n z2min ≤ n z2i
where the last inequality holds for all i = 1, . . . , n. This implies y ≤ n2 z2i for the
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observed test statistic y and any study i = 1, . . . , n and with equation (4) we obtain
Pr{χ2(1) ≥ n2 z2i }/2n ≤ pH.
If pH ≤ αH is required for a claim of success at level αH, then obviously Pr{χ2(1) ≥
n2 z2i }/2n ≤ αH must hold, which can be re-written as zi ≥
√
cH/n with cH as defined
in (5). The restriction on the corresponding p-values is
pi ≤ 1−Φ(
√
cH/n). (6)
This is a necessary but not sufficient restriction on the study-specific p-values for a
claim of success.
It is also possible to derive the corresponding sufficient bound. Assume all p-values
are equal (i. e. z21 = . . . = z
2
n), then the condition χ2 = n z2i ≥ cH implies zi ≥
√
cH/
√
n.
Note that the sufficient bound on zi differs from the corresponding necessary bound
only by the multiplicative factor
√
n. The restriction on the corresponding p-values is
pi ≤ 1−Φ(
√
cH/
√
n). (7)
αH bound n = 2 n = 3 n = 4 n = 5 n = 6
1/1600 necessary 0.065 0.17 0.26 0.32 0.37
sufficient 0.016 0.053 0.099 0.15 0.20
1/31574 necessary 0.028 0.11 0.19 0.26 0.30
sufficient 0.0034 0.017 0.041 0.071 0.10
1/3488556 necessary 0.0075 0.058 0.13 0.19 0.24
sufficient 0.00029 0.0032 0.011 0.024 0.04
Table 2: Necessary and sufficient bounds on the one-sided study-specific p-values for
overall significance level αH and different number of studies n
The necessary and sufficient bounds in (6) and (7), respectively, are shown in Table 2
for αH = 1/1600 (the two-trials rule), 1/31574 (the “four-sigma rule”) and 1/3488556
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(the “five-sigma rule”). For example, for n = 2 studies and level 1/1600, the require-
ment pi ≤ 0.065, i = 1, 2, is necessary for claiming success. If one of the two studies has
a p-value larger than 0.065, a claim of success at level αH = 1/1600 is thus impossible,
no matter how small the other p-value is. The stricter requirement pi ≤ 0.016, i = 1, 2,
is sufficient for a claim of success at that level. For the five-sigma level 1/3488556, the
necessary bound is 0.0075 for n = 2 and 0.058 for n = 3 studies. The sufficient bound
is 0.00029 for n = 2 and 0.0032 for n = 3.
3. Comparison with the two-trials rule
The two-trials rule for drug approval is usually implemented by requiring that each
study is significant at the one-sided level α = 1/40 = 0.025, so the probability of n = 2
significant positive trials when there is no treatment effect is α2 = 1/1600 = 0.000625.
Suppose both studies have a positive effect in the right direction and the observed
test statistic (1) is χ2 = y. The harmonic mean χ2 p-value (4) now reduces to pH =[
1−Φ(√y)] /2. A critical value for the test statistic (1) can also be calculated using
(5). For αH = 0.0252 and n = 2 we obtain the value cH = 9.14.
Figure 1 compares the region for drug approval based on the two-trials rule with the
proposed harmonic mean χ2 test. Shown are two versions of the latter, the “controlled”
version based on αH = 0.0252, i. e. critical value cH = 9.14 and a “liberal” version with
critical value 7.68. This has been computed by equating the right-hand side of (7)
with 0.025 and solving for cH. The liberal version thus ensures that approval by the
two-trials rule always leads to approval by the harmonic mean χ2 test. The Type-I
error rate of the liberal version is 0.00139, inflated by a factor of 2.23 compared to the
α2 = 0.0252 level.
Also shown in Figure 1 is the corresponding region for drug approval of the pooled
and combined method, both controlled at Type-I error 0.0252. Both methods com-
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Figure 1: Comparison of different approaches for drug approval as function of the two
p-values p1 and p2 (left) and the two Z-values Z1 and Z2 (right), respect-
ively. The acceptance region of the two-trials rule is shown in grey. The
acceptance regions of the other methods is below (left) or above (right) the
corresponding curves. All methods control the Type-I error rate at 0.000625
except for the liberal version of the harmonic mean χ2 test, which has Type-I
error rate 0.00139. The contour lines in the right plot represent the distribu-
tion of Z1 and Z2 under the alternative if the two studies have 80% power at
the one-sided 2.5% significance level.
pensate smaller intersections with the two-trials rejection region with additional re-
gions of rejection where one of the trials shows only weak or even no evidence for an
effect. It is interesting to see that the harmonic mean χ2 test is closer to the two-trials
rule than Stouffer’s pooled or Fisher’s combined method, particularly good to see in
the z-scale shown in the right plot of Figure 1. The latter two suffer from the possibil-
ity of approval if one of the p-values is very small while the other one is far away from
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traditional significance. A highly significant p-value may actually guarantee approval
through Fisher’s method, no matter how large the p-value from the other study is.
This is not possible for Stouffer’s method, but it may still happen that the effects from
the two studies go in different directions with the combined effect being significant.
As a consequence, the sufficient p-value bound, shown in the left plot of Figure 1, is
considerably smaller for the pooled (0.011) and combined (0.008) method than for the
controlled harmonic mean χ2 test (0.016). These features make both the pooled and
the combined method less suitable for drug approval.
For comparison, the two-trials rule has the necessary and sufficient conditions pi ≤
0.025, i = 1, 2. The harmonic mean χ2 test can be significant only if both p-values are
small (< 0.065). This has been discussed in Section 2 and can also be seen from Figure
2, which shows the conditional power for drug approval given the p-value p1 from
the first study. The values represent the power to detect the observed effect from the
first study with a second study of equal design and sample size. The two-trials rule
has conditional power as described by Goodman (1992), but with a discontinuity at
0.025. The power curves of the two harmonic tests (calculated as described in Held
(2020, Section 4)) are smooth, quickly approaching zero at p1 = 0.065 respectively
p1 = 0.083. Both the combined and the pooled method have longer tails with non-
zero conditional power even for a larger p-value of the first study. Here the conditonal
power of the combined method can be derived as 1−Φ[Φ−1(p1)−Φ−1(min{1, c/p1})]
where c = Pr(χ2(4) ≥ αH). The conditonal power of the pooled method turns out to
be 1−Φ[2Φ−1(p1)−
√
2Φ−1(αH)].
3.1. Project power
Of central interest in drug development is often the “project power” for a claim of suc-
cess (Maca et al., 2002) before the two trials are conducted. It is well known (Matthews,
2006) that under the alternative that was used to power the study, the distribution of
12
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Figure 2: Power for drug approval at level 0.000625 conditional on the one-sided p-
value of the first study. Power values of exactly zero are omitted.
Z1 (and Z2) is N(µ, 1) where
µ = Φ−1(1− α) +Φ−1(1− β).
We can thus simulate independent Z1 and Z2 for α = 0.025 and different values of the
power 1− β and compute the proportion of trial results with drug approval at level
α2. This is shown in Table 3 for the different methods.
As expected, the two-trials rule gives project power equal to (1− β)2, since the two
trials are assumed to be independent, each significant with probability 1 − β. The
project power of the Type-I error controlled harmonic mean χ2 test is 4 to 7 percentage
points larger, depending on the power of the two studies. The project power of the
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combined and pooled methods are even larger but this comes at the price that approval
may be granted even if one of the trials was not sufficiently convincing on its own.
Power two-trials rule harmonic combined pooled
70 49 56 58 61
80 64 71 74 77
90 81 87 90 91
95 90 94 96 97
Table 3: The probability of drug approval (in %) as a function of the original power of
the two studies
3.2. Application
Two advantages of the proposed method are that it allows for weighting and is read-
ily applicable to the case where results from more than 2 studies are available. For
practical illustration, I revisit the data shown in Table 1 on the effect of Carvedilol
on mortality. Note that all p-values are below the necessary success bound 0.32 at
the level of the two-trials rule, compare Table 2. Only the p-value of study #239 is
above the sufficient bound 0.15, otherwise we could already claim success with the
unweighted harmonic mean χ2 test.
Fisher (1999a) reports Fisher’s combined p-value, which is 0.00013. Stouffer’s pooled
test gives the p-value 0.00009. The harmonic mean χ2 test gives 0.00048 (unweighted)
and 0.00034 (weighted), so somewhat larger values. For the latter the weights have
been chosen inversely proportional to the squared standard errors of the associated
log hazard ratios also shown in Table 1, see Appendix B for further details. Note
that all these p-values are smaller than the two-trials threshold 0.000625. However,
Stouffer’s weighted test doesn’t meet the two-trials criterion (p = 0.0014).
Suppose now that the p-value in study #223 (the largest study with the smallest
standard error) is 2 times as large, i. e. 0.256 rather than 0.128. This would be con-
sidered as unimportant by many scientists, as both p-values are non-significant any-
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way and far away from the 0.025 significance threshold. Keeping the standard error
of the log relative risk fixed, the relative risk reduction in this study is now 17%
rather than 28%. But this change has a large effect on the proposed methods: The
unweighted and weighted harmonic mean χ2 test p-values increase by a factor of 2.5
and 7.9 to 0.0012 and 0.0027, respectively, so both would now fail the 0.0252 criterion
for drug approval. The unweighted and weighted versions of Stouffer’s test p-values
increase by a factor of 2.3 and 3.5 to 0.00021 and 0.005, respectively. Fisher’s combined
p-value increases only by a factor of 1.7 to 0.00022, which is still below the 0.000625
threshold, just as Stouffer’s unweighted test. This illustrates that the harmonic mean
χ2 test is more sensitive to studies with unconvincing results, i. e. relatively small effect
sizes with large p-values.
4. Calibrating the sceptical p-value
Replication studies are conducted in order to investigate whether an original finding
can be confirmed in an independent study. The sceptical p-value pS has been proposed
in Held (2020) as a method to assess the degree of replication success. The sceptical
p-value combines statistical significance of the two studies with a comparison of effect
and sample sizes. A small sceptical p-value pS < αS can be interpreted as replication
success at level αS.
The sceptical p-value pS depends on the two p-values of the original and replication
study and on the variance ratio c, which can be written as the sample size of the
replication study relative to the sample size of the original study. If the two studies
have the same sample size (c = 1), the sceptical p-value depends only on the two
p-values p1 and p2 in a symmetric fashion. This has similarities to the two-trials rule
which requires two independent significant studies for drug approval. As usual in
this context we will consider only one-sided p-values where the standard significance
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level is α = 0.025. Without loss of generality we consider the alternative H1: θ > 0
against the point null H0: θ = 0.
The framework in Held (2020) was developed for two-sided p-values but a one-
sided version of the sceptical p-value has also been proposed. Assume that θˆ1 ≥ 0 and
θˆ2 ≥ 0 are both positive. For c = 1, the one-sided sceptical p-value pS = 1−Φ(|zS|)
can be computed from
z2S = 1/(1/z
2
1 + 1/z
2
2) (8)
where z1 = 1− Φ−1(p1) is the test statistic based on the one-sided p-value p1 of the
first study and z2 = 1−Φ−1(p2) is the test statistic based on the one-sided p-value p2
of the second study. The direct connection z2S = z
2
H/4 to the harmonic mean χ
2 test
statistic (1) makes it easy to choose the threshold αS such that the sceptical p-value has
the same Type-I error as the two-trials rule with Type-I error 0.0252. With (5) we obtain
the threshold cS = cH/4 = 9.14/4 = 2.285 for (8), which corresponds to a one-sided
sceptical p-value threshold of αS = 0.065. It is no accident that this is exactly the same
value as the necessary bound on the n = 2 individual p-values for a claim of success,
as shown in Table 2. The reason is that the property max{p1, p2} ≤ pS combined with
the requirement pS ≤ αS implies that max{p1, p2} ≤ αS must hold.
Alternatively we may pick the nominal threshold αS = α. The Type-I error rate of the
nominal threshold is 0.000022, 28 times smaller than α2. One may also re-consider the
liberal threshold, i. e. the smallest threshold where p1 ≤ α and p2 ≤ α is sufficient for
pS ≤ αS. For α = 0.025 we obtain the liberal threshold αS = 0.083 and we know from
Section 3 that the Type-I error rate of the liberal threshold is 2.23 times larger than the
controlled threshold α2. All three thresholds are displayed for various values of α in
Figure 3 together with the corresponding type-I error rate values.
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Figure 3: The three thresholds αS for the one-sided sceptical p-value as a function of α
(left). The right plot gives the corresponding Type-I error rate curves, where
the controlled threshold has Type-I error rate α2.
5. Discussion
There is considerable variation of clinical trial evidence for newly approved therapies
(Downing et al., 2014). New methods are required to provide better inferences for
the assessment of pivotal trials supporting novel therapeutic approval. The harmonic
mean χ2 test is an attractive alternative to the two-trials rule as it has more power at
the same Type-I error rate and avoids the evidence paradoxes that may occur close
to the 0.025 threshold. It provides a principled extension to substantiate research
findings from more than two trials, requesting each trial to be convincing on its own,
and allows for weights.
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The method implicitly assumes that each of the individual trials is well-powered
for realistic treatment effects. The risk that the harmonic mean test fails increases
substantially, if some of the trials have low power. Implementation of this new method
may therefore be seen as a means to ensure sufficiently powered individual studies.
The proposed method is different from the harmonic mean p-value (Good, 1958;
Wilson, 2019; Held, 2019), where the null distribution is more difficult to compute
(Wilson, 2019, Section 1 of Supplementary Material). The harmonic mean χ2 test is not
directly linked to an effect estimate and a confidence interval. However, the test could
easily be inverted to obtain a confidence interval based on study-specific test statistics
Zi = (θˆi − µ)/σi for non-zero means µ. More research is needed to investigate this
possibility.
The two-trials rule is the standard for many indications, including many neuro-
generative and cardiovascular diseases. However, approval of treatments in areas of
high medical need may not follow the two-trials rule. An alternative approach is con-
ditional approval based on “adaptive pathways” (European Medical Agency, 2016),
where a temporary license is is granted based on an initial positive trial. A second
post-marketing clinical trial is then often required to confirm or revoke the initial de-
cision (Zhang et al., 2019). This setting has much in common with replication studies
that try to confirm original results in independent investigations (Roes, 2020) and the
re-calibration of the sceptical p-value described in Section 4 may be useful to explore
in this setting.
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Appendix
A. The null distribution of the harmonic mean χ2 test statistic
Under the null hypothesis, Zi, i = 1, . . . , n, is standard normal distributed, so Z2i is χ
2
with 1 degree of freedom, i. e. a gamma G(1/2, 1/2) distribution. The random variable
Xi = 1/Z2i is therefore inverse gamma distributed, Xi ∼ IG(1/2, 1/2), also known
as the standard Lévy distribution: Xi ∼ Levy(0, 1). More generally, the Levy(0, c)
distribution corresponds to the IG(1/2, c/2) distribution and belongs to the class of
stable distributions (Uchaikin and Zolotarev, 1999, Section 2.3).
Now Z1, . . . , Zn are assume to be independent, so X1, . . . , Xn are also independent
and we are interested in the distribution of the sum X = X1 + . . .+Xn, compare equa-
tion (1). The standard Lévy distribution is known to be stable, which means that the
sum of independent standard Lévy random variables is again a Lévy random vari-
able: X ∼ Levy(0, n2), which corresponds to a IG(1/2, n2/2) distribution. Therefore
1/X = 1/∑ni=1 1/Z
2
i follows a G(1/2, n
2/2) distribution and χ2 = n2/X follows a
G(1/2, 1/2), i. e. a χ2 distribution with one degree of freedom.
The weighted version X = w1X1 + . . . + wnXn is also a Lévy random variable, X ∼
Levy(0,w2) where w = ∑ni=1
√
wi, see Nolan (2018, Proposition 1.17). Therefore χ2w =
w2/X also follows a χ2 distribution with one degree of freedom.
B. Further details on the Carvedilol example
The data shown in Table 1 are taken from Fisher (1999a, Table 1) for the outcome mor-
tality. The discussion on Fisher (1999a, page 17) suggests that the p-values reported in
the table come from a log-rank test. The relative risks reported in the table appear to be
“instantaneous relative risks”, i. e. hazard ratios. I have calculated the standard error
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of the log hazard ratios from the limits of the 95% confidence intervals also reported
in the table. Note that there is an apparent discrepancy between the p-value and the
confidence interval reported for Study 240, with the one-sided log-rank p-value being
just significant (p=0.0245) whereas the 95% confidence interval for the hazard ratio
runs from 0.04 to 1.14 and includes the reference value 1. Leaving rounding errors
aside, the corresponding one-sided p-value from a Wald-test is p=0.038. This does
not much affect the harmonic mean χ2 test but the two-trials rule would obviously no
longer be fulfilled. The difference between log-rank and Wald is still surprising, but
a similar example has been reported in Collett (2003, Example 3.3). I have decided to
use the log-rank p-values as reported, whereas the standard errors of log hazard ratios
are only used to weight the harmonic mean χ2 test statistic. Finally note that mortal-
ity was not the primary endpoint of the different studies, but Fisher (1999a) argues
that “it is the most important endpoint” and “almost always of primary importance to
patients and their loved ones”.
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